Skip to main content
Top
Published in: Fibrogenesis & Tissue Repair 1/2011

Open Access 01-12-2011 | Research

Assessment of proteolytic degradation of the basement membrane: a fragment of type IV collagen as a biochemical marker for liver fibrosis

Authors: Sanne S Veidal, Morten A Karsdal, Arkadiusz Nawrocki, Martin R Larsen, Yueqin Dai, Qinlong Zheng, Per Hägglund, Ben Vainer, Helene Skjøt-Arkil, Diana J Leeming

Published in: Fibrogenesis & Tissue Repair | Issue 1/2011

Login to get access

Abstract

Background

Collagen deposition and an altered matrix metalloproteinase (MMP) expression profile are hallmarks of fibrosis. Type IV collagen is the most abundant structural basement membrane component of tissue, which increases 14-fold during fibrogenesis in the liver. Proteolytic degradation of collagens by proteases produces small fragments, so-called neoepitopes, which are released systemically. Technologies investigating MMP-generated fragments of collagens may provide more useful information than traditional serological assays that crudely measure total protein. In the present study, we developed an ELISA for the quantification of a neoepitope generated by MMP degradation of type IV collagen and evaluated the association of this neoepitope with liver fibrosis in two animal models.

Methods

Type IV collagen was degraded in vitro by a variety of proteases. Mass spectrometric analysis revealed more than 200 different degradation fragments. A specific peptide sequence, 1438'GTPSVDHGFL'1447 (CO4-MMP), in the α1 chain of type IV collagen generated by MMP-9 was selected for ELISA development. ELISA was used to determine serum levels of the CO4-MMP neoepitope in two rat models of liver fibrosis: inhalation of carbon tetrachloride (CCl4) and bile duct ligation (BDL). The levels were correlated to histological findings using Sirius red staining.

Results

A technically robust assay was produced that is specific to the type IV degradation fragment, GTPSVDHGFL. CO4-MMP serum levels increased significantly in all BDL groups compared to baseline, with a maximum increase of 248% seen two weeks after BDL. There were no changes in CO4-MMP levels in sham-operated rats. In the CCl4 model, levels of CO4-MMP were significantly elevated at weeks 12, 16 and 20 compared to baseline levels, with a maximum increase of 88% after 20 weeks. CO4-MMP levels correlated to Sirius red staining results.

Conclusion

This ELISA is the first assay developed for assessment of proteolytic degraded type IV collagen, which, by enabling quantification of basement membrane degradation, could be relevant in investigating various fibrogenic pathologies. The CO4-MMP degradation fragment was highly associated with liver fibrosis in the two animal models studied.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Gressner OA, Weiskirchen R, Gressner AM: Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta. 2007, 381: 107-113. 10.1016/j.cca.2007.02.038.CrossRefPubMed Gressner OA, Weiskirchen R, Gressner AM: Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta. 2007, 381: 107-113. 10.1016/j.cca.2007.02.038.CrossRefPubMed
3.
go back to reference Bedossa P, Dargère D, Paradis V: Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003, 38: 1449-1457.CrossRefPubMed Bedossa P, Dargère D, Paradis V: Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003, 38: 1449-1457.CrossRefPubMed
4.
go back to reference Maharaj B, Maharaj RJ, Leary WP, Cooppan RM, Naran AD, Pirie D, Pudifin DJ: Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet. 1986, 1: 523-525.CrossRefPubMed Maharaj B, Maharaj RJ, Leary WP, Cooppan RM, Naran AD, Pirie D, Pudifin DJ: Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet. 1986, 1: 523-525.CrossRefPubMed
5.
go back to reference Veidal SS, Bay-Jensen AC, Tougas G, Karsdal MA, Vainer B: Serum markers of liver fibrosis: combining the BIPED classification and the neo-epitope approach in the development of new biomarkers. Dis Markers. 2010, 28: 15-28.PubMedCentralCrossRefPubMed Veidal SS, Bay-Jensen AC, Tougas G, Karsdal MA, Vainer B: Serum markers of liver fibrosis: combining the BIPED classification and the neo-epitope approach in the development of new biomarkers. Dis Markers. 2010, 28: 15-28.PubMedCentralCrossRefPubMed
6.
go back to reference Rowe RG, Weiss SJ: Breaching the basement membrane: who, when and how?. Trends Cell Biol. 2008, 18: 560-574. 10.1016/j.tcb.2008.08.007.CrossRefPubMed Rowe RG, Weiss SJ: Breaching the basement membrane: who, when and how?. Trends Cell Biol. 2008, 18: 560-574. 10.1016/j.tcb.2008.08.007.CrossRefPubMed
7.
go back to reference Hudson BG, Reeders ST, Tryggvason K: Type IV collagen: structure, gene organization, and role in human diseases: molecular basis of Goodpasture and Alport syndromes and diffuse leiomyomatosis. J Biol Chem. 1993, 268: 26033-26036.PubMed Hudson BG, Reeders ST, Tryggvason K: Type IV collagen: structure, gene organization, and role in human diseases: molecular basis of Goodpasture and Alport syndromes and diffuse leiomyomatosis. J Biol Chem. 1993, 268: 26033-26036.PubMed
8.
go back to reference Gubler MC: Inherited diseases of the glomerular basement membrane. Nat Clin Pract Nephrol. 2008, 4: 24-37. 10.1038/ncpneph0671.CrossRefPubMed Gubler MC: Inherited diseases of the glomerular basement membrane. Nat Clin Pract Nephrol. 2008, 4: 24-37. 10.1038/ncpneph0671.CrossRefPubMed
9.
go back to reference Van Agtmael T, Bruckner-Tuderman L: Basement membranes and human disease. Cell Tissue Res. 2010, 339: 167-188. 10.1007/s00441-009-0866-y.CrossRefPubMed Van Agtmael T, Bruckner-Tuderman L: Basement membranes and human disease. Cell Tissue Res. 2010, 339: 167-188. 10.1007/s00441-009-0866-y.CrossRefPubMed
10.
go back to reference Hemmann S, Graf J, Roderfeld M, Roeb E: Expression of MMPs and TIMPs in liver fibrosis: a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol. 2007, 46: 955-975. 10.1016/j.jhep.2007.02.003.CrossRefPubMed Hemmann S, Graf J, Roderfeld M, Roeb E: Expression of MMPs and TIMPs in liver fibrosis: a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol. 2007, 46: 955-975. 10.1016/j.jhep.2007.02.003.CrossRefPubMed
11.
go back to reference Kirimlioglu H, Kirimlioglu V, Yilmaz S: Expression of matrix metalloproteinases 2 and 9 in donor liver, cirrhotic liver, and acute rejection after human liver transplantation. Transplant Proc. 2008, 40: 3574-3577. 10.1016/j.transproceed.2008.09.033.CrossRefPubMed Kirimlioglu H, Kirimlioglu V, Yilmaz S: Expression of matrix metalloproteinases 2 and 9 in donor liver, cirrhotic liver, and acute rejection after human liver transplantation. Transplant Proc. 2008, 40: 3574-3577. 10.1016/j.transproceed.2008.09.033.CrossRefPubMed
12.
go back to reference Karsdal MA, Henriksen K, Leeming DJ, Mitchell P, Duffin K, Barascuk N, Klickstein L, Aggarwal P, Nemirovskiy O, Byrjalsen I, Qvist P, Bay-Jensen AC, Dam EB, Madsen SH, Christiansen C: Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers. 2009, 14: 181-202. 10.1080/13547500902777608.CrossRefPubMed Karsdal MA, Henriksen K, Leeming DJ, Mitchell P, Duffin K, Barascuk N, Klickstein L, Aggarwal P, Nemirovskiy O, Byrjalsen I, Qvist P, Bay-Jensen AC, Dam EB, Madsen SH, Christiansen C: Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers. 2009, 14: 181-202. 10.1080/13547500902777608.CrossRefPubMed
13.
go back to reference Combet C, Blanchet C, Geourjon C, Deléage G: NPS@: network protein sequence analysis. Trends Biochem Sci. 2000, 25: 147-150. 10.1016/S0968-0004(99)01540-6.CrossRefPubMed Combet C, Blanchet C, Geourjon C, Deléage G: NPS@: network protein sequence analysis. Trends Biochem Sci. 2000, 25: 147-150. 10.1016/S0968-0004(99)01540-6.CrossRefPubMed
14.
go back to reference Gefter ML, Margulies DH, Scharff MD: A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells. Somatic Cell Genet. 1977, 3: 231-236. 10.1007/BF01551818.CrossRefPubMed Gefter ML, Margulies DH, Scharff MD: A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells. Somatic Cell Genet. 1977, 3: 231-236. 10.1007/BF01551818.CrossRefPubMed
15.
go back to reference Segovia-Silvestre T, Reichenbach V, Fernández-Varo G, Vassiliadis E, Barascuk N, Morales-Ruiz M, Karsdal MA, Jiménez W: Circulating CO3-610, a degradation product of collagen III, closely reflects liver collagen and portal pressure in rats with fibrosis. Fibrogenesis Tissue Repair. 2011, 4: 19-10.1186/1755-1536-4-19.PubMedCentralCrossRefPubMed Segovia-Silvestre T, Reichenbach V, Fernández-Varo G, Vassiliadis E, Barascuk N, Morales-Ruiz M, Karsdal MA, Jiménez W: Circulating CO3-610, a degradation product of collagen III, closely reflects liver collagen and portal pressure in rats with fibrosis. Fibrogenesis Tissue Repair. 2011, 4: 19-10.1186/1755-1536-4-19.PubMedCentralCrossRefPubMed
16.
go back to reference Clariá J, Jiménez W: Renal dysfunction and ascites in carbon tetrachloride-induced cirrhosis in rats. In The Liver and the Kidney. 1999, Boston: Blackwell Science, 379-396. Clariá J, Jiménez W: Renal dysfunction and ascites in carbon tetrachloride-induced cirrhosis in rats. In The Liver and the Kidney. 1999, Boston: Blackwell Science, 379-396.
17.
go back to reference Muñoz-Luque J, Ros J, Fernández-Varo G, Tugues S, Morales-Ruiz M, Alvarez CE, Friedman SL, Arroyo V, Jiménez W: Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther. 2008, 324: 475-483.PubMedCentralCrossRefPubMed Muñoz-Luque J, Ros J, Fernández-Varo G, Tugues S, Morales-Ruiz M, Alvarez CE, Friedman SL, Arroyo V, Jiménez W: Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther. 2008, 324: 475-483.PubMedCentralCrossRefPubMed
18.
go back to reference Gressner AM, Weiskirchen R: Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-β as major players and therapeutic targets. J Cell Mol Med. 2006, 10: 76-99. 10.1111/j.1582-4934.2006.tb00292.x.PubMedCentralCrossRefPubMed Gressner AM, Weiskirchen R: Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-β as major players and therapeutic targets. J Cell Mol Med. 2006, 10: 76-99. 10.1111/j.1582-4934.2006.tb00292.x.PubMedCentralCrossRefPubMed
19.
go back to reference Murawaki Y, Koda M, Okamoto K, Mimura K, Kawasaki H: Diagnostic value of serum type IV collagen test in comparison with platelet count for predicting the fibrotic stage in patients with chronic hepatitis C. J Gastroenterol Hepatol. 2001, 16: 777-781. 10.1046/j.1440-1746.2001.02515.x.CrossRefPubMed Murawaki Y, Koda M, Okamoto K, Mimura K, Kawasaki H: Diagnostic value of serum type IV collagen test in comparison with platelet count for predicting the fibrotic stage in patients with chronic hepatitis C. J Gastroenterol Hepatol. 2001, 16: 777-781. 10.1046/j.1440-1746.2001.02515.x.CrossRefPubMed
20.
go back to reference Walsh KM, Fletcher A, MacSween RN, Morris AJ: Basement membrane peptides as markers of liver disease in chronic hepatitis C. J Hepatol. 2000, 32: 325-330. 10.1016/S0168-8278(00)80079-3.CrossRefPubMed Walsh KM, Fletcher A, MacSween RN, Morris AJ: Basement membrane peptides as markers of liver disease in chronic hepatitis C. J Hepatol. 2000, 32: 325-330. 10.1016/S0168-8278(00)80079-3.CrossRefPubMed
21.
go back to reference Barascuk N, Veidal SS, Larsen L, Larsen DV, Larsen MR, Wang J, Zheng Q, Xing R, Cao Y, Rasmussen LM, Karsdal MA: A novel assay for extracellular matrix remodeling associated with liver fibrosis: an enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem. 2010, 43: 899-904. 10.1016/j.clinbiochem.2010.03.012.CrossRefPubMed Barascuk N, Veidal SS, Larsen L, Larsen DV, Larsen MR, Wang J, Zheng Q, Xing R, Cao Y, Rasmussen LM, Karsdal MA: A novel assay for extracellular matrix remodeling associated with liver fibrosis: an enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem. 2010, 43: 899-904. 10.1016/j.clinbiochem.2010.03.012.CrossRefPubMed
22.
go back to reference Vassiliadis E, Veidal SS, Simonsen H, Larsen DV, Vainer B, Chen X, Zheng Q, Karsdal MA, Leeming DJ: Immunological detection of the type V collagen propeptide fragment, PVCP-1230, in connective tissue remodeling associated with liver fibrosis. Biomarkers. 2011, 16: 426-433. 10.3109/1354750X.2011.584131.CrossRefPubMed Vassiliadis E, Veidal SS, Simonsen H, Larsen DV, Vainer B, Chen X, Zheng Q, Karsdal MA, Leeming DJ: Immunological detection of the type V collagen propeptide fragment, PVCP-1230, in connective tissue remodeling associated with liver fibrosis. Biomarkers. 2011, 16: 426-433. 10.3109/1354750X.2011.584131.CrossRefPubMed
23.
go back to reference Veidal SS, Vassiliadis E, Bay-Jensen AC, Tougas G, Vainer B, Karsdal MA: Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats. Fibrogenesis Tissue Repair. 2010, 3: 5-10.1186/1755-1536-3-5.PubMedCentralCrossRefPubMed Veidal SS, Vassiliadis E, Bay-Jensen AC, Tougas G, Vainer B, Karsdal MA: Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats. Fibrogenesis Tissue Repair. 2010, 3: 5-10.1186/1755-1536-3-5.PubMedCentralCrossRefPubMed
24.
go back to reference Veidal SS, Vassiliadis E, Barascuk N, Zhang C, Segovia-Silvestre T, Klickstein L, Larsen MR, Qvist P, Christiansen C, Vainer B, Karsdal MA: Matrix metalloproteinase-9-mediated type III collagen degradation as a novel serological biochemical marker for liver fibrogenesis. Liver Int. 2010, 30: 1293-1304. 10.1111/j.1478-3231.2010.02309.x.CrossRefPubMed Veidal SS, Vassiliadis E, Barascuk N, Zhang C, Segovia-Silvestre T, Klickstein L, Larsen MR, Qvist P, Christiansen C, Vainer B, Karsdal MA: Matrix metalloproteinase-9-mediated type III collagen degradation as a novel serological biochemical marker for liver fibrogenesis. Liver Int. 2010, 30: 1293-1304. 10.1111/j.1478-3231.2010.02309.x.CrossRefPubMed
25.
go back to reference Leeming DJ, Larsen DV, Zhang C, Hi Y, Veidal SS, Nielsen RH, Henriksen K, Zheng Q, Barkholt V, Riis BJ, Byrjalsen I, Qvist P, Karsdal MA: Enzyme-linked immunosorbent serum assays (ELISAs) for rat and human N-terminal pro-peptide of collagen type I (PINP): assessment of corresponding epitopes. Clin Biochem. 2010, 43: 1249-1256. 10.1016/j.clinbiochem.2010.07.025.CrossRefPubMed Leeming DJ, Larsen DV, Zhang C, Hi Y, Veidal SS, Nielsen RH, Henriksen K, Zheng Q, Barkholt V, Riis BJ, Byrjalsen I, Qvist P, Karsdal MA: Enzyme-linked immunosorbent serum assays (ELISAs) for rat and human N-terminal pro-peptide of collagen type I (PINP): assessment of corresponding epitopes. Clin Biochem. 2010, 43: 1249-1256. 10.1016/j.clinbiochem.2010.07.025.CrossRefPubMed
26.
go back to reference Vassiliadis E, Larsen DV, Clausen RE, Veidal SS, Barascuk N, Larsen L, Simonsen H, Silvestre TS, Hansen C, Overgaard T, Leeming DJ, Karsdal MA: Measurement of CO3-610, a potential liver biomarker derived from matrix metalloproteinase-9 degradation of collagen type iii, in a rat model of reversible carbon-tetrachloride-induced fibrosis. Biomark Insights. 2011, 6: 49-58.PubMedCentralCrossRefPubMed Vassiliadis E, Larsen DV, Clausen RE, Veidal SS, Barascuk N, Larsen L, Simonsen H, Silvestre TS, Hansen C, Overgaard T, Leeming DJ, Karsdal MA: Measurement of CO3-610, a potential liver biomarker derived from matrix metalloproteinase-9 degradation of collagen type iii, in a rat model of reversible carbon-tetrachloride-induced fibrosis. Biomark Insights. 2011, 6: 49-58.PubMedCentralCrossRefPubMed
27.
go back to reference Vassiliadis E, Veidal SS, Barascuk N, Mullick JB, Clausen RE, Larsen L, Simonsen H, Larsen DV, Bay-Jensen AC, Segovia-Silvestre T, Leeming DJ, Karsdal MA: Measurement of matrix metalloproteinase 9-mediated collagen type III degradation fragment as a marker of skin fibrosis. BMC Dermatol. 2011, 11: 6-10.1186/1471-5945-11-6.PubMedCentralCrossRefPubMed Vassiliadis E, Veidal SS, Barascuk N, Mullick JB, Clausen RE, Larsen L, Simonsen H, Larsen DV, Bay-Jensen AC, Segovia-Silvestre T, Leeming DJ, Karsdal MA: Measurement of matrix metalloproteinase 9-mediated collagen type III degradation fragment as a marker of skin fibrosis. BMC Dermatol. 2011, 11: 6-10.1186/1471-5945-11-6.PubMedCentralCrossRefPubMed
28.
go back to reference Gressner OA, Weiskirchen R, Gressner AM: Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. J Cell Mol Med. 2007, 11: 1031-1051. 10.1111/j.1582-4934.2007.00092.x.PubMedCentralCrossRefPubMed Gressner OA, Weiskirchen R, Gressner AM: Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. J Cell Mol Med. 2007, 11: 1031-1051. 10.1111/j.1582-4934.2007.00092.x.PubMedCentralCrossRefPubMed
29.
go back to reference Hsu CC, Lai SC: Matrix metalloproteinase-2, -9 and -13 are involved in fibronectin degradation of rat lung granulomatous fibrosis caused by Angiostrongylus cantonensis. Int J Exp Pathol. 2007, 88: 437-443. 10.1111/j.1365-2613.2007.00554.x.PubMedCentralCrossRefPubMed Hsu CC, Lai SC: Matrix metalloproteinase-2, -9 and -13 are involved in fibronectin degradation of rat lung granulomatous fibrosis caused by Angiostrongylus cantonensis. Int J Exp Pathol. 2007, 88: 437-443. 10.1111/j.1365-2613.2007.00554.x.PubMedCentralCrossRefPubMed
30.
go back to reference Garnero P, Borel O, Byrjalsen I, Ferreras M, Drake FH, McQueney MS, Foged NT, Delmas PD, Delaissé JM: The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem. 1998, 273: 32347-32352. 10.1074/jbc.273.48.32347.CrossRefPubMed Garnero P, Borel O, Byrjalsen I, Ferreras M, Drake FH, McQueney MS, Foged NT, Delmas PD, Delaissé JM: The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem. 1998, 273: 32347-32352. 10.1074/jbc.273.48.32347.CrossRefPubMed
31.
go back to reference Gioia M, Fasciglione GF, Monaco S, Iundusi R, Sbardella D, Marini S, Tarantino U, Coletta M: pH dependence of the enzymatic processing of collagen I by MMP-1 (fibroblast collagenase), MMP-2 (gelatinase A), and MMP-14 ectodomain. J Biol Inorg Chem. 2010, 15: 1219-1232. 10.1007/s00775-010-0680-8.CrossRefPubMed Gioia M, Fasciglione GF, Monaco S, Iundusi R, Sbardella D, Marini S, Tarantino U, Coletta M: pH dependence of the enzymatic processing of collagen I by MMP-1 (fibroblast collagenase), MMP-2 (gelatinase A), and MMP-14 ectodomain. J Biol Inorg Chem. 2010, 15: 1219-1232. 10.1007/s00775-010-0680-8.CrossRefPubMed
32.
go back to reference Sukhova GK, Schönbeck U, Rabkin E, Schoen FJ, Poole AR, Billinghurst RC, Libby P: Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation. 1999, 99: 2503-2509.CrossRefPubMed Sukhova GK, Schönbeck U, Rabkin E, Schoen FJ, Poole AR, Billinghurst RC, Libby P: Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation. 1999, 99: 2503-2509.CrossRefPubMed
33.
go back to reference Charni-Ben TN, Desmarais S, Bay-Jensen AC, Delaissé JM, Percival MD, Garnero P: The type II collagen fragments Helix-II and CTX-II reveal different enzymatic pathways of human cartilage collagen degradation. Osteoarthritis Cartilage. 2008, 16: 1183-1191. 10.1016/j.joca.2008.02.008.CrossRef Charni-Ben TN, Desmarais S, Bay-Jensen AC, Delaissé JM, Percival MD, Garnero P: The type II collagen fragments Helix-II and CTX-II reveal different enzymatic pathways of human cartilage collagen degradation. Osteoarthritis Cartilage. 2008, 16: 1183-1191. 10.1016/j.joca.2008.02.008.CrossRef
34.
go back to reference Murawaki Y, Ikuta Y, Koda M, Yamada S, Kawasaki H: Comparison of serum 7S fragment of type IV collagen and serum central triple-helix of type IV collagen for assessment of liver fibrosis in patients with chronic viral liver disease. J Hepatol. 1996, 24: 148-154. 10.1016/S0168-8278(96)80023-7.CrossRefPubMed Murawaki Y, Ikuta Y, Koda M, Yamada S, Kawasaki H: Comparison of serum 7S fragment of type IV collagen and serum central triple-helix of type IV collagen for assessment of liver fibrosis in patients with chronic viral liver disease. J Hepatol. 1996, 24: 148-154. 10.1016/S0168-8278(96)80023-7.CrossRefPubMed
Metadata
Title
Assessment of proteolytic degradation of the basement membrane: a fragment of type IV collagen as a biochemical marker for liver fibrosis
Authors
Sanne S Veidal
Morten A Karsdal
Arkadiusz Nawrocki
Martin R Larsen
Yueqin Dai
Qinlong Zheng
Per Hägglund
Ben Vainer
Helene Skjøt-Arkil
Diana J Leeming
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Fibrogenesis & Tissue Repair / Issue 1/2011
Electronic ISSN: 1755-1536
DOI
https://doi.org/10.1186/1755-1536-4-22

Other articles of this Issue 1/2011

Fibrogenesis & Tissue Repair 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.